Catalent(CTLT) - 2021 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company's net revenue for Q1 fiscal 2022 was over $1 billion, representing a 21% increase as reported or 20% in constant currency compared to Q1 fiscal 2021 [4] - Adjusted EBITDA for the first quarter was $252 million, up 44% on both an as-reported and constant-currency basis compared to the prior year [4][7] - Adjusted net income for Q1 was $128 million or $0.71 per diluted share, an increase from $0.43 per diluted share in the same period last year [4][9] Business Line Data and Key Metrics Changes - The Biologics segment saw organic net revenue growth of 44%, with segment EBITDA increasing by 56% compared to the first quarter of last year [5][7] - The Softgel and Oral Technologies segment experienced a 9% increase in net revenue, driven by demand for prescription and consumer health products [5][7] - The Clinical Supply Services segment posted modest net revenue growth of 2% compared to the prior year, with profitability impacted by costs related to new facility openings [8] Market Data and Key Metrics Changes - The Biologics segment represented 53% of net revenue in Q1 fiscal 2022, up from 44% in Q1 fiscal 2021 [7] - The backlog for the Clinical Supply Services segment was $515 million, a 20% increase from the previous year [8] Company Strategy and Development Direction - The company is focused on long-term growth through organic investments and strategic acquisitions, including the recent acquisition of Viterra for $1 billion [5][9] - The acquisition of Viterra is expected to enhance the company's growth rate in the Softgel and Oral Technologies segment from 3%-5% to 6%-8% [5] - Continued investments in biologics capacity are planned, including expansions at facilities in Bloomington, Indiana, and Anagni, Italy [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for COVID-19 related products and the recovery of consumer health segments [4][12] - The company anticipates a deceleration in growth rates for the Biologics segment as it compares against higher demand levels from the previous fiscal year [7] - Management highlighted the importance of maintaining capacity to meet customer needs and the ongoing challenges related to supply chain disruptions [32] Other Important Information - The company raised $1.1 billion through term loans and senior notes to fund the Viterra acquisition, resulting in a cash balance of over $2 billion [9] - Capital expenditures are expected to be approximately 15%-16% of net revenue for fiscal 2022, primarily driven by growth investments in the biologics segment [9] Q&A Session Summary Question: Thoughts on organic growth and guidance raise - Management indicated that the guidance raise reflects strong organic performance across business units, particularly in Biologics and consumer health segments [12] Question: Demand environment for Softgel business - Management noted a positive demand profile and a return to organic growth, with expectations for continued strength in the second half of the year [14] Question: Vaccine production outlook - Management sees vaccines as a long-term franchise, with ongoing demand for vaccinations and boosters expected to sustain growth [36] Question: Update on Madison site and commercial therapies - Management aims to bring a commercial product to the Madison site within the next 12 to 18 months, with a robust pipeline in place [18] Question: Insights on backlog growth and future revenue opportunities - Management expressed confidence in returning to long-term growth rates, with significant development activity in both SOT and OSD segments [22] Question: Impact of supply chain disruptions on guidance - Management confirmed that supply chain challenges and wage inflation have been factored into the guidance, with proactive measures taken to mitigate impacts [31][32]